NO994042D0 - Transdermal anordning til levering av testosteron - Google Patents

Transdermal anordning til levering av testosteron

Info

Publication number
NO994042D0
NO994042D0 NO994042A NO994042A NO994042D0 NO 994042 D0 NO994042 D0 NO 994042D0 NO 994042 A NO994042 A NO 994042A NO 994042 A NO994042 A NO 994042A NO 994042 D0 NO994042 D0 NO 994042D0
Authority
NO
Norway
Prior art keywords
testosterone
delivery
transdermal device
transdermal
terpene
Prior art date
Application number
NO994042A
Other languages
English (en)
Other versions
NO994042L (no
Inventor
John C Hedenstrom
Michael L Husberg
Shari L Myszka
Matthew T Scholz
Original Assignee
Minnesota Mining & Mfg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minnesota Mining & Mfg filed Critical Minnesota Mining & Mfg
Publication of NO994042D0 publication Critical patent/NO994042D0/no
Publication of NO994042L publication Critical patent/NO994042L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
NO994042A 1997-02-28 1999-08-20 Transdermal anordning til levering av testosteron NO994042L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3927497P 1997-02-28 1997-02-28
PCT/US1998/003943 WO1998037871A1 (en) 1997-02-28 1998-02-27 Transdermal device for the delivery of testosterone

Publications (2)

Publication Number Publication Date
NO994042D0 true NO994042D0 (no) 1999-08-20
NO994042L NO994042L (no) 1999-10-26

Family

ID=21904596

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994042A NO994042L (no) 1997-02-28 1999-08-20 Transdermal anordning til levering av testosteron

Country Status (16)

Country Link
US (1) US6132760A (no)
EP (1) EP0979072B1 (no)
JP (1) JP2001517216A (no)
KR (1) KR20000075804A (no)
AT (1) ATE293960T1 (no)
AU (1) AU735944B2 (no)
BR (1) BR9807786A (no)
CA (1) CA2281876A1 (no)
DE (1) DE69829961T2 (no)
HU (1) HUP0001748A3 (no)
NO (1) NO994042L (no)
NZ (1) NZ337135A (no)
PL (1) PL335410A1 (no)
SK (1) SK116199A3 (no)
TR (1) TR199902104T2 (no)
WO (1) WO1998037871A1 (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2793689B1 (fr) * 1999-05-19 2001-08-24 Pf Medicament Dispositif transdermique pour l'administration de testosterone ou d'un de ses derives
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US6582724B2 (en) 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US6586000B2 (en) * 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
US6673363B2 (en) 1999-12-16 2004-01-06 Dermatrends, Inc. Transdermal and topical administration of local anesthetic agents using basic enhancers
US6562369B2 (en) 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
AU2001292781A1 (en) * 2000-09-19 2002-04-02 National Starch And Chemical Investment Holding Corporation Acryl adhesive useful in transdermal drug delivery systems
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
EP1390383B1 (en) * 2001-05-11 2012-02-29 Isis Pharmaceuticals, Inc. Antisense permeation enhancers
KR100517637B1 (ko) * 2001-12-21 2005-09-28 씨제이 주식회사 섬수 정제 엑스 및 인삼 정제 엑스를 함께 함유하면서다른 정유 생약 성분은 함유하지 않는 조루증의 예방 및치료용 조성물
US20040062794A1 (en) * 2002-09-30 2004-04-01 Lee Shulman 17Beta- estradiol/levonorgestrel transdermal patch for hormone replacement therapy
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
IL152573A (en) 2002-10-31 2009-11-18 Transpharma Medical Ltd A system for the transmission through the skin of a medical preparation against vomiting and nausea
MY141815A (en) 2003-04-30 2010-06-30 Purdue Pharma Lp Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US8883769B2 (en) * 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
US20040259852A1 (en) * 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
AU2004249295A1 (en) * 2003-06-20 2004-12-29 Viral Genomix, Inc. Compositions for and methods for treating HIV
EP1684734A2 (en) * 2003-11-18 2006-08-02 3M Innovative Properties Company Olanzapine containing transdermal drug delivery compositions
JP4567998B2 (ja) * 2004-03-22 2010-10-27 コスメディ製薬株式会社 親水性粘着剤を用いた親水性皮膚外用粘着剤組成物および親水性貼付剤
CN101287470B (zh) 2005-10-12 2012-10-17 优尼麦德药物股份有限公司 改良的睾酮凝胶及使用方法
US20080132475A1 (en) * 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
US20100016264A1 (en) * 2007-12-05 2010-01-21 Connor Charles G Treatment for dry eye using testosterone and progestagen
FR2924942B1 (fr) * 2007-12-14 2012-06-15 Pf Medicament Compositions pharmaceutiques transcutanees contenant une hormone steroidienne
US8445037B2 (en) * 2008-10-28 2013-05-21 A. M. Todd Company Volatile distillate by-product of mint oil that promotes absorption and/or bioavailability of compounds of bio-medical and nutritional interest
US9642863B2 (en) 2010-11-18 2017-05-09 White Mountain Pharma, Inc. Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein
CN105916951A (zh) * 2013-12-20 2016-08-31 3M创新有限公司 抗菌压敏粘合剂体系
UY35923A (es) * 2013-12-30 2015-07-31 Rhodia Operations ?composiciones pesticidas agrícolas?.
US11813354B1 (en) 2019-01-11 2023-11-14 Shear Kershman Laboratories, Inc Trans-mucosal delivery system for testosterone

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU622162B2 (en) * 1988-04-22 1992-04-02 Ciba-Geigy Ag Transdermal monolith systems
AU6712090A (en) * 1989-10-13 1991-05-16 Watson Laboratories, Inc. Drug delivery systems and matrix therefor
DE69122464T2 (de) * 1990-03-30 1997-02-20 Yasunori Morimoto Transdermal absorbierbares mittel mit morphin hydrochlorid
US5152997A (en) * 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5164190A (en) * 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
EP0491076A1 (en) * 1990-12-19 1992-06-24 Theratech, Inc. Penetration enhancement with multi-component system of N-aliphatic pyrrolidones with lower alcohols
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
DE4210165A1 (de) * 1991-07-30 1993-02-04 Schering Ag Transdermale therapeutische systeme
US5676968A (en) * 1991-10-31 1997-10-14 Schering Aktiengesellschaft Transdermal therapeutic systems with crystallization inhibitors
US5230897A (en) * 1991-10-31 1993-07-27 G. D. Searle & Co. Transdermal pentamidine
CA2075517C (en) * 1992-04-01 1997-03-11 John Wick Transdermal patch incorporating a polymer film incorporated with an active agent
JP3548195B2 (ja) * 1993-05-27 2004-07-28 リンテック株式会社 経皮吸収型製剤
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
JP3908795B2 (ja) * 1994-11-29 2007-04-25 久光製薬株式会社 ケトチフェン含有経皮投与製剤

Also Published As

Publication number Publication date
PL335410A1 (en) 2000-04-25
AU735944B2 (en) 2001-07-19
SK116199A3 (en) 2000-01-18
EP0979072B1 (en) 2005-04-27
HUP0001748A3 (en) 2001-03-28
WO1998037871A1 (en) 1998-09-03
BR9807786A (pt) 2000-02-22
DE69829961D1 (de) 2005-06-02
CA2281876A1 (en) 1998-09-03
NO994042L (no) 1999-10-26
AU6539098A (en) 1998-09-18
EP0979072A1 (en) 2000-02-16
ATE293960T1 (de) 2005-05-15
DE69829961T2 (de) 2006-02-23
TR199902104T2 (xx) 2000-04-21
US6132760A (en) 2000-10-17
HUP0001748A2 (hu) 2000-12-28
KR20000075804A (ko) 2000-12-26
JP2001517216A (ja) 2001-10-02
NZ337135A (en) 2001-07-27

Similar Documents

Publication Publication Date Title
NO994042D0 (no) Transdermal anordning til levering av testosteron
DK0973497T3 (da) Farmaceutisk bæreanordning, egnet til udlevering af farmaceutiske forbindelser til slimhindeoverflade
KR960702300A (ko) 에스트라디올을 함유하는 경피 치료 시스템 (transdermal therapeutic system containing estradiol)
WO1999012529A3 (de) Transdermales therapeutisches system mit haftklebender reservoirschicht und unidirektional elastischer rückschicht
DE19680582D2 (de) Hormonpflaster
HUP9901991A2 (hu) Transzdermális eszköz flurbiprofén átadására
WO2000062763A3 (en) Carrier patch for the delivery of agents to the skin
ZA952364B (en) Dressing
AU2895392A (en) Transdermal therapeutic systems containing crystallization inhibitors
MY119665A (en) Pressure sensitive adhesive sheet and method of use thereof
DK0659081T3 (da) Dexpanthenol-holdigt plaster til transdermal applikation af steroidhormoner
HUP0204448A2 (en) Trnasdermal therapeutic system for the delivery of lerisetron
DE60011120D1 (de) Vorrichtung zur klebemittelübertragung
DE50005092D1 (de) Polyurethanträgerfolie mit hydrophobierungsmitteln für filmpflaster
ES2112748A1 (es) Papel de empapelar que se puede aplicar oquitar facialmente de un sustrato.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application